ClinicaliQ Trial Snapshot
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) — Recruiting • Phase III • Oncology • NCT06925737.
- What is being tested: Ifinatamab deruxtecan (I-DXd/MK-2400), a novel targeted therapy designed to treat metastatic castration-resistant prostate cancer (mCRPC), with the primary objective of evaluating its efficacy and safety profile in this patient population.
- Patient eligibility overview: The study targets men with mCRPC who have progressed despite castration therapy; specific eligibility criteria typically include confirmed metastatic disease, adequate organ function, and prior treatment history, though full criteria would be detailed in the protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
Eligibility Snapshot
- : The main inclusion criteria include but are not limited to the following: * Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology * Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to Screening * Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography (CT)/magnetic resonance imaging (MRI) * Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after at least 8 weeks of treatment * Has provided tumor tissue from a core or excisional biopsy from soft tissue not previously irradiated and obtained after disease progression on the most recent prior therapy * Has recovered from adverse events (AEs) due to previous anticancer therapies
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.